Avadel Pharmaceuticals (AVDL) Current Deferred Revenue (2016 - 2019)
Historic Current Deferred Revenue for Avadel Pharmaceuticals (AVDL) over the last 11 years, with Q1 2019 value amounting to $115000.0.
- Avadel Pharmaceuticals' Current Deferred Revenue changed N/A to $115000.0 in Q1 2019 from the same period last year, while for Mar 2019 it was $115000.0, marking a year-over-year change of. This contributed to the annual value of $114000.0 for FY2018, which is 9431.99% down from last year.
- As of Q1 2019, Avadel Pharmaceuticals' Current Deferred Revenue stood at $115000.0.
- In the past 5 years, Avadel Pharmaceuticals' Current Deferred Revenue registered a high of $5.1 million during Q4 2015, and its lowest value of -$1.3 million during Q2 2015.
- Its 5-year average for Current Deferred Revenue is $2.1 million, with a median of $2.1 million in 2015.
- Data for Avadel Pharmaceuticals' Current Deferred Revenue shows a peak YoY increase of 128662.42% (in 2015) and a maximum YoY decrease of 23098.24% (in 2015) over the last 5 years.
- Avadel Pharmaceuticals' Current Deferred Revenue (Quarter) stood at $5.1 million in 2015, then plummeted by 56.59% to $2.2 million in 2016, then dropped by 9.72% to $2.0 million in 2017, then plummeted by 94.32% to $114000.0 in 2018, then increased by 0.88% to $115000.0 in 2019.
- Its Current Deferred Revenue was $115000.0 in Q1 2019, compared to $114000.0 in Q4 2018 and $1.7 million in Q3 2018.